LEADER 03940nam 2200637 a 450 001 9910144011403321 005 20211007205910.0 010 $a1-282-34805-1 010 $a9786612348051 010 $a0-470-51539-2 010 $a0-470-51540-6 035 $a(CKB)1000000000376023 035 $a(EBL)470448 035 $a(OCoLC)609849347 035 $a(SSID)ssj0000305014 035 $a(PQKBManifestationID)11259778 035 $a(PQKBTitleCode)TC0000305014 035 $a(PQKBWorkID)10285230 035 $a(PQKB)11605647 035 $a(MiAaPQ)EBC470448 035 $a(EXLCZ)991000000000376023 100 $a19970602d1997 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aOligonucleotides as therapeutic agents$b[electronic resource] /$f[editors, Derek J. Chadwick (Organizer) and Gail Cardew] 210 $aChichester ;$aNew York $cWiley$d1997 215 $a1 online resource (262 p.) 225 1 $aCiba Foundation symposium ;$v209 300 $aProceedings of the Symposium on Oligonucleotides as Therapeutic Agents, held at Ciba Foundation on 7-9 January 1997. 311 $a0-471-97279-7 320 $aIncludes bibliographical references and indexes. 327 $aOLIGONUCLEOTIDES AS THERAPEUTIC AGENTS; Contents; Participants; Introduction; Oligoncleotide analogues: an overview; Phosphorothioate oligodeox ynucleotides: large-scale synthesis and analysis, impurity characterization, and the effects of phosphorus stereochemistry; Discovering antisense reagents by hybridization of RNA to oligonucleotide arrays; Pharrnacokinetics of oligonucleotides in cell culture; Pharrnacokinetics of oligonucleotides; Controversies in the cellular pharmacology of oligodeox ynucleotides; Sequence-specific control of gene expression by antigene and clamp oligonucleotides 327 $aFirst- and second-generation antisense oligonucleotide inhibitors targeted against human c-raf kinaseDifferential oligonucleotide activity in cell culture versus mouse models; Structure-activity relationships in cell culture; Progress in antisense therapeutics discovery and development; Oligonucleotide therapeutics for human leukemia; Therapeutic applications of catalytic antisense RNAs (ribozymes); Exogenous application of riboaymes for inhibiting gene expression; Efficient process technologies for the preparation of oligonucleotides 327 $aIn vivo production of oligodeoxyribonucleotides of specific sequences: application to antisense DNASummary; Index of contributors; Subject index 330 $aThe use of oligonucleotides as therapeutic agents rests upon their ability to interfere, in a sequence-specific manner, with the fundamental machinery of protein synthesis either by binding to the mRNAs transcribed from a gene or by binding directly to a target gene. This approach can be used not only for inhibition of the synthesis of host proteins but also of those required by invading pathogens. Potential therapeutic applications are enormous, ranging over hypertension, cardiovascular disease, autoimmune disease, vital and other parasitic infections (especially HIV), and cancer. This book d 410 0$aCiba Foundation symposium ;$v209. 606 $aOligonucleotides$xTherapeutic use$vCongresses 606 $aAntisense nucleic acids$xTherapeutic use$vCongresses 608 $aElectronic books. 615 0$aOligonucleotides$xTherapeutic use 615 0$aAntisense nucleic acids$xTherapeutic use 676 $a615 676 $a615.31 701 $aChadwick$b Derek$091632 701 $aCardew$b Gail$0857118 712 12$aSymposium on Oligonucleotides as Therapeutic Agents$f(1997 :$eCiba Foundation) 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910144011403321 996 $aOligonucleotides as therapeutic agents$92013976 997 $aUNINA